BDSI BEMA fentanyl NDA in Q2’07
This article was originally published in Pharmaceutical Approvals Monthly
BioDelivery Sciences plans to submit an NDA for its BEMA fentanyl oral adhesive disc in the second quarter of 2007, the company says Sept. 20. The Morrissville, N.C. firm is targeting use in breakthrough pain and projects $250 mil. in peak sales (1Pharmaceutical Approvals Monthly March 2006, p. 19). On Sept. 26, BDSI announced that the Research Advisory Panel of California approved the restart of two Phase III protocols of the proprietary fentanyl formulation. BDSI received a "not approvable" letter Feb. 28 for its antiemetic Emezine (prochlorperazine) for use in severe nausea and vomiting and subsequently began highlighting its BEMA formulations, which include a long-acting analgesic and zolpidem (Sanofi-Aventis' Ambien and tentatively approved generics)...
You may also be interested in...
BioDelivery Sciences International is touting the potential of its flagship analgesic pipeline and downplaying Emezine for severe nausea and vomiting after receiving a "not approvable" letter from FDA Feb. 28 for the latter treatment.
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.